NJ-ADVA
14.6.2022 09:02:09 CEST | Business Wire | Press release
ADVA (FSE: ADV) today announced that Edge, a regional research and education (R&E) network based in New Jersey, has expanded its deployment of the ADVA ALM fiber monitoring solution to improve real-time service performance and reduce operating costs. The in-service assurance technology enables Edge to rapidly detect and locate faults in its optical transport infrastructure throughout New York, New Jersey and Pennsylvania. With more complete network visibility, Edge can respond in an instant to fiber issues and fix problems before services are affected. The ability to immediately identify areas of concern and precisely target maintenance efforts also helps reduce truck rolls and improves cost-efficiency.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220613005463/en/
“As the Edge network and member base expands, we continuously strive to enhance our reliability and client experience. To do so, Edge has relied on ADVA technology for years and we count on leveraging their continued innovation to benefit our members. ADVA’s ALM assurance solution delivers real-time info on the quality of our fiber. It tells us exactly where repairs are needed, and that has proven to be a big help in terms of time and cost savings. In the past, we might know there was a problem causing intermittent disruption somewhere between New York and Philadelphia, for example. It could take days to find using traditional manual OTDR testing. Now we can react quickly and accurately, and there’s no more time wasted on site visits,” said a spokesperson for Edge. “The ALM lets us troubleshoot issues before they impact end users and deliver even more robust and efficient services, helping our customers advance research, education and economic development across the region.”
The ADVA ALM maximizes resource efficiency by providing comprehensive fiber health assurance. It now instantly alerts Edge to any fiber breaks or abnormal attenuation. The solution is also helping bolster network security by notifying maintenance teams of tapping attempts. The non-intrusive service-agnostic device identifies the exact geographic location of events through an intuitive graphical user interface. Featuring fanless operation and low-power consumption, the ultra-compact ALM enhances operational efficiency and sustainability across Edge’s infrastructure.
“The Edge network is a vital resource for the scientists, educators and healthcare providers they serve. We’re proud to support its team as they deliver even more to help organizations digitize their operations and achieve their strategic goals,” commented John Scherzinger, SVP of sales, Americas at ADVA. “Our ALM solution provides Edge with an intricate understanding of its optical fiber infrastructure. The tiny device has already had a big impact, helping the service provider diagnose and remedy issues while making maintenance easier and more environmentally friendly.”
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com
.
About Edge
Founded in 2000, Edge, a 501(c)(3) nonprofit corporation, serves as a purpose-built research and education wide area network and technology solutions partner. Edge connects members with affordable, easy access to high-performance optical networking, commodity Internet and Internet2 services, and a variety of technology-powered products, solutions, and services. The Edge member consortium consists of colleges and universities, K-12 schools and districts, government entities, healthcare networks, and businesses spread throughout the continental US. The group is governed by the New Jersey Presidents’ Council with offices in Newark, Princeton, and Wall Township, NJ. For more information, please visit: www.njedge.net
.
Published by:
ADVA Optical Networking SE, Munich, Germany
www.adva.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20220613005463/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Thales Builds Cryptographic Security for the Age of AI and Post-Quantum Computing14.9.2026 09:00:00 CEST | Press release
Thales launches Luna 8, a new hardware security module (HSM) to provide future-ready, quantum resistant security to protect critical data and applications Powered by a Thales designed cryptographic processor, it delivers unparalleled performance, enhanced protection and the flexibility to adapt to new security needs Drawing on decades of cryptographic expertise, Luna 8 combines trusted security with support for emerging technologies, including post quantum cryptography According to the 2026 Thales Data Threat Report, the threat of Harvest Now, Decrypt Later (HNDL) attacks was the top-cited risk, with 59% of organizations reporting that they are prototyping and evaluating post-quantum cryptography (PQC) algorithms to prepare for the quantum era. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260804748922/en/ ©Thales To help organizations turn this readiness into deployment,Thales, a global leader in advanced technologies, tod
U.S. FDA Accepts New Drug Application Under Priority Review for Takeda’s Zasocitinib in Moderate-to-Severe Plaque Psoriasis, with Potential to Redefine Oral Treatment Expectations14.9.2026 09:00:00 CEST | Press release
Acceptance is based on pivotal Phase 3 data demonstrating rapid, durable and consistent skin clearance, including in high-impact sites, in a convenient once-daily pill Results from nearly 3,000 patients support potential for next-generation TYK2 inhibitor to redefine oral treatment expectations in psoriasis The Prescription Drug User Fee Act (PDUFA) target action date is in the first quarter of calendar year 2027 Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) accepted its New Drug Application (NDA) under Priority Review for zasocitinib (TAK-279) for the treatment of adults with moderate-to-severe plaque psoriasis. Zasocitinib is an investigational, next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, which demonstrated rapid, durable and consistent skin clearance in Phase 3 plaque psoriasis studies.1-3 Addressing unmet needs in psoriasis treatment “Despite progress in psoriasis care, there remains a need for highly
SWISSto12 and Mitsubishi Electric Corporation Announce Strategic Partnership14.9.2026 09:00:00 CEST | Press release
The Memorandum of Understanding (MoU) and additional contract signal a new phase of collaboration on market development in the Asia Pacific (APAC) region SWISSto12 today announced a memorandum of understanding (MoU) with Mitsubishi Electric Corporation (MELCO) (TOKYO: 6503) to pursue joint opportunities on advanced payloads, radio frequency (RF) products, and market development in Japan and the APAC region. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260914982179/en/ Masahiko Arai, Executive Officer and Group President, Defense & Space Systems, Mitsubishi Electric, and Dr. Emile de Rijk, Chief Executive Officer, SWISSto12 Joint opportunities will leverage MELCO’s extensive satellite system expertise and integration capabilities together with SWISSto12’s proprietary 3D-printing designs and processes that form the foundation of its next-generation payloads—smaller, lighter, highly performant, yet built in materially shorter
Focused Support Launches Cavok STRIKE to Expand Link-16 Participation Across the Joint Force14.9.2026 07:00:00 CEST | Press release
Extending Link-16 interoperability without platform-level hardware integration Focused Support LLC today announced the launch of Cavok STRIKE, an integrated software capability that expands the Link-16 tactical battlespace picture by enabling additional operational platforms to participate in the Link-16 network. Modern battlefields have increasing numbers of unmanned systems, sensors, and supporting platforms operating throughout the joint battlespace. The rapid proliferation of Group 1, 2, and 3 UAS, including both expendable and recoverable systems, has created a growing need to integrate these assets into the broader tactical network. Many of these platforms provide operationally relevant information but have historically remained outside the Link-16 network due to limitations in size, weight, power, platform integration complexity, or acquisition cost. Cavok STRIKE addresses this gap by enabling platforms to participate in the Link-16 network as non-command-and-control participant
Fujirebio Expands Access to Blood-based Neurology Testing in Brazil with ANVISA Market Authorization for Lumipulse® G NfL Blood and Lumipulse G pTau 217 Plasma14.9.2026 07:00:00 CEST | Press release
H.U. Group Holdings Inc. and its wholly owned subsidiary Fujirebio today announced that the Brazilian Health Regulatory Agency (ANVISA) has granted market authorization for the Lumipulse G NfL Blood and Lumipulse G pTau 217 Plasma assays for use on the fully automated LUMIPULSE® G immunoassay platform in Brazil. “ANVISA authorization of the Lumipulse G NfL Blood and Lumipulse G pTau 217 Plasma assays marks another important step in our mission to expand access to reliable, clinically meaningful blood-based biomarkers for clinicians and patients worldwide,” said Christiaan De Wilde, CEO of Fujirebio Europe N.V. “By making both neurological biomarker assays available to laboratories on a single, fully automated platform, we are helping support more informed clinical decision-making across a broad range of neurological conditions and throughout the diagnostic pathway.” The Brazilian ANVISA authorizations are based on the already CE marked in vitro diagnostics (IVD) approvals of these two
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom